325 related articles for article (PubMed ID: 36077601)
1. Updated Neoadjuvant Treatment Landscape for Early Triple Negative Breast Cancer: Immunotherapy, Potential Predictive Biomarkers, and Novel Agents.
Garufi G; Carbognin L; Schettini F; Seguí E; Di Leone A; Franco A; Paris I; Scambia G; Tortora G; Fabi A
Cancers (Basel); 2022 Aug; 14(17):. PubMed ID: 36077601
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant therapy for triple-negative breast cancer: potential predictive biomarkers of activity and efficacy of platinum chemotherapy, PARP- and immune-checkpoint-inhibitors.
Garufi G; Palazzo A; Paris I; Orlandi A; Cassano A; Tortora G; Scambia G; Bria E; Carbognin L
Expert Opin Pharmacother; 2020 Apr; 21(6):687-699. PubMed ID: 32052646
[TBL] [Abstract][Full Text] [Related]
3. Early Triple Negative Breast Cancer: Conventional Treatment and Emerging Therapeutic Landscapes.
Diana A; Carlino F; Franzese E; Oikonomidou O; Criscitiello C; De Vita F; Ciardiello F; Orditura M
Cancers (Basel); 2020 Mar; 12(4):. PubMed ID: 32235297
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy for Early-Stage Triple Negative Breast Cancer: Is Earlier Better?
Song F; Tarantino P; Garrido-Castro A; Lynce F; Tolaney SM; Schlam I
Curr Oncol Rep; 2024 Jan; 26(1):21-33. PubMed ID: 38198112
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant Therapy for Patients with Triple Negative Breast Cancer (TNBC).
Liedtke C; Rody A
Rev Recent Clin Trials; 2017; 12(2):73-80. PubMed ID: 28270088
[TBL] [Abstract][Full Text] [Related]
6. Research advances and new challenges in overcoming triple-negative breast cancer.
Zong Y; Pegram M
Cancer Drug Resist; 2021; 4(3):517-542. PubMed ID: 34888495
[TBL] [Abstract][Full Text] [Related]
7. BRCA Mutational Status is a Promising Predictive Biomarker for Platinum- based Chemotherapy in Triple-Negative Breast Cancer.
Tazzite A; Jouhadi H; Benider A; Nadifi S
Curr Drug Targets; 2020; 21(10):962-973. PubMed ID: 32013831
[TBL] [Abstract][Full Text] [Related]
8. Triple-negative breast cancer: treatment challenges and solutions.
Collignon J; Lousberg L; Schroeder H; Jerusalem G
Breast Cancer (Dove Med Press); 2016; 8():93-107. PubMed ID: 27284266
[TBL] [Abstract][Full Text] [Related]
9. Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer.
Agostinetto E; Losurdo A; Nader-Marta G; Santoro A; Punie K; Barroso R; Popovic L; Solinas C; Kok M; de Azambuja E; Lambertini M
Expert Opin Investig Drugs; 2022 Jun; 31(6):567-591. PubMed ID: 35240902
[TBL] [Abstract][Full Text] [Related]
10. The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics.
Anders CK; Abramson V; Tan T; Dent R
Am Soc Clin Oncol Educ Book; 2016; 35():34-42. PubMed ID: 27249684
[TBL] [Abstract][Full Text] [Related]
11. Current Treatment Landscape for Early Triple-Negative Breast Cancer (TNBC).
Lee J
J Clin Med; 2023 Feb; 12(4):. PubMed ID: 36836059
[TBL] [Abstract][Full Text] [Related]
12. Optimal Choice of Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer: Clinical Insights.
Lucas MW; Kelly CM
Cancer Manag Res; 2022; 14():2493-2506. PubMed ID: 35999966
[TBL] [Abstract][Full Text] [Related]
13. Biomarkers of DNA Repair and Related Pathways: Significance of Treatment in Triple-Negative Breast Cancer.
Guo W; Lin L; He X; He F; Wang C; Chen N; Wang Y
Crit Rev Oncog; 2017; 22(5-6):427-437. PubMed ID: 29604922
[TBL] [Abstract][Full Text] [Related]
14. Potential Predictive and Prognostic Value of Biomarkers Related to Immune Checkpoint Inhibitor Therapy of Triple-Negative Breast Cancer.
Tan Q; Yin S; Zhou D; Chi Y; Man X; Li H
Front Oncol; 2022; 12():779786. PubMed ID: 35646659
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant Treatment for Triple Negative Breast Cancer: Recent Progresses and Challenges.
Lee JS; Yost SE; Yuan Y
Cancers (Basel); 2020 May; 12(6):. PubMed ID: 32486021
[TBL] [Abstract][Full Text] [Related]
16. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.
Isaacs J; Anders C; McArthur H; Force J
Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085
[TBL] [Abstract][Full Text] [Related]
17. Integrating Immunotherapy Into the Treatment Landscape for Patients With Triple-Negative Breast Cancer.
Dixon-Douglas J; Loibl S; Denkert C; Telli M; Loi S
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-13. PubMed ID: 35649211
[TBL] [Abstract][Full Text] [Related]
18. Advances in the Management of Early-Stage Triple-Negative Breast Cancer.
Bhardwaj PV; Wang Y; Brunk E; Spanheimer PM; Abdou YG
Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569851
[TBL] [Abstract][Full Text] [Related]
19. The advance of adjuvant treatment for triple-negative breast cancer.
Ge J; Zuo W; Chen Y; Shao Z; Yu K
Cancer Biol Med; 2021 Aug; 19(2):187-201. PubMed ID: 34448553
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint inhibitors for triple-negative breast cancer: From immunological mechanisms to clinical evidence.
Farshbafnadi M; Pastaki Khoshbin A; Rezaei N
Int Immunopharmacol; 2021 Sep; 98():107876. PubMed ID: 34146865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
